Turning Point Therapeutics, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • April 8th, 2019 • Turning Point Therapeutics, Inc. • Pharmaceutical preparations • New York
Turning Point Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [•] shares of the Company’s common stock, par value $0.0001 per share (“Stock”, and such shares the “Firm Shares”) and, at the election of the Underwriters, up to [•] additional shares (the “Optional Shares”) of Stock (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively called the “Shares”).
INDEMNITY AGREEMENTIndemnity Agreement • April 8th, 2019 • Turning Point Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of , 20 , is made by and between TURNING POINT THERAPEUTICS, INC., a Delaware corporation (the “Company”), and (“Indemnitee”).
TURNING POINT THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT for ANNETTE C. NORTHEmployment Agreement • April 8th, 2019 • Turning Point Therapeutics, Inc. • Pharmaceutical preparations • California
This Executive Employment Agreement (this “Agreement”), is made and entered into as of March 20, 2019, by and between Annette C. North (“Executive”) and Turning Point Therapeutics, Inc. (the “Company”).
